Climb Bio, Inc.
Climb Bio, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 38.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| April 15, 2027 | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Trial Milestone | Phase 1 |
| August 15, 2027 | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | Trial Milestone | Phase 1/Phase 2 |
| September 15, 2027 | A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | Trial Milestone | Phase 1/Phase 2 |
| October 15, 2027 | A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | Trial Milestone | Phase 2 |
Track CLYM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CLYM in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.